Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 161 Oyster Point Blvd SOUTH SAN FRANCISCO CA 94080-1910 |
Tel: | N/A |
Website: | https://www.denalitherapeutics.com |
IR: | See website |
Key People | ||
Ryan J. Watts President, Chief Executive Officer, Director | Alexander O. Schuth Chief Financial Officer, Chief Operating Officer, Company Secretary | Carole Ho Chief Medical Officer |
Business Overview |
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson's disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome). |
Financial Overview |
For the three months ended 31 March 2024, Denali Therapeutics Inc revenues decreased from $35.1M to $0K. Net loss decreased 7% to $101.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research & Development Expense - Balanci decrease of 19% to $90.7M (expense), Interest income (expense), net increase of 44% to $15.9M (income), Selling. |
Employees: | 375 as of Mar 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,674M as of Mar 31, 2024 |
Annual revenue (TTM): | $295.39M as of Mar 31, 2024 |
EBITDA (TTM): | -$199.30M as of Mar 31, 2024 |
Net annual income (TTM): | -$137.25M as of Mar 31, 2024 |
Free cash flow (TTM): | -$425.11M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 142,609,036 as of Apr 30, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |